Up next

Autoplay

BRUKINSA® (zanubrutinib) safety profile vs ibrutinib with Dr Anthony Nguyen

0 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Dr Nguyen, a community-based medical oncologist, discusses the impact of decreased side effects after switching his patients to BRUKINSA.

BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:
• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
• Waldenström's macroglobulinemia (WM)

Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and embryo-fetal toxicity. In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were
neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

Please see full Prescribing Information: brukinsa.com/prescribing-information.pdf

This content is intended for US Healthcare Professionals only. Learn more at:
https://www.brukinsa.com/hcp/

Show more
0 Comments sort Sort By

Up next

Autoplay